Nanexa publishes interim report for January-June 2024
NEX-22 clinical trial initiated and proceeding with dose escalation as planned
Significant events during the second quarter 2024
- Nanexa announced in April that additional supplements had been requested from the European Medicines Agency in the ongoing review process of the clinical trial application for the Phase I study with NEX-22.
- Nanexa announced in mid-May that the European Medicines Agency had approved the company's clinical trial application for the Phase I study with NEX-22, following review of the submitted complete data.
- At Nanexa's Annual General Meeting on May 15, it was resolved in accordance with the Board's proposal, among other things, to elect Hanna Tilus as a new Board member and to authorize the Board to decide on a rights issue and a directed issue.
- Nanexa announced in June that the company's Phase I study with NEX-22 for the treatment of type 2 diabetes had been initiated with dosing of the first patient.
- Nanexa announced that Cecilia Danckwardt-Lillieström will take over as Chief Financial Officer as of September 1, 2024, as the current CFO Björn Svanström has chosen to leave the company.
Significant events after the end of the period
- Nanexa announced that the company’s Phase I study for type 2 diabetes continues dose escalation according to plan with its long-acting depot formulation of the GLP-1 analog liraglutide.
Financial overview
1 April – 30 June 2024
- Turnover amounted to: TSEK 5,657 (7,655)
- Operating profit (EBIT) amounted to: TSEK -6,124 (-10,067)
- Profit after tax amounted to: TSEK -6,012 (-9,951)
- Earnings per share amounted to: SEK -0.04 (-0.16)
- Cash flow for the period amounted to: TSEK -6,529 (-22,141)
- Cash and cash equivalents at end of period: TSEK 41,311 (38,358)
1 January – 30 June 2024
- Turnover amounted to: TSEK 13,411 (15,828)
- Operating profit (EBIT) amounted to: TSEK -9,487 (-18,770)
- Profit after tax amounted to: TSEK -8,835 (-18,553)
- Earnings per share amounted to: SEK -0.07 (-0.31)
- Cash flow for the period amounted to: TSEK -23,857 (-42,824)
- Cash and cash equivalents at end of period: TSEK 41,311 (38,358)
Figures in brackets refer to the corresponding period in the previous year.
The entire report is available on the company’s website: https://nanexa.com/en/financial-reports/.
Report commentary, 27 August at 11:30am CET
A live commentary with CEO David Westberg will take place on August 27 at 11:30am via Infront Direkt Studios and viewers will have the opportunity to ask questions via chat.
The report commentary will be available here.
The report comment will also be published on Nanexa's website afterwards.
